

A Short Note on Proliferative Diabetic Retinopathy

Daniel S*

Department of Endocrinology, Diabetes, Metabolism, and Nutrition, The Mayo Clinic, Rochester, Minnesota, United States

Letter

Diabetic retinopathy, also known as diabetic eye complaint (DED), is a medical condition in which damage occurs to the retina due to diabetes mellitus. It's a leading cause of blindness in developed countries. Diabetic retinopathy affects up to 80 percent of those who have had diabetes for 20 years or further. At least 90% of new cases could be reduced with proper treatment and monitoring of the eyes. The longer a person has diabetes, the advanced his or her chances of developing diabetic retinopathy. Each time in the United States, diabetic retinopathy accounts for 12% of all new cases of blindness. It's also the leading cause of blindness in people aged 20 to 64.

Diabetic retinopathy is the result of damage to the small blood vessels and neurons of the retina [1]. The foremost changes leading to diabetic retinopathy include narrowing of the retinal highways associated with reduced retinal blood inflow; dysfunction of the neurons of the inner retina, followed in later stages by changes in the function of the external retina, associated with subtle changes in visual function; dysfunction of the blood-retinal barrier, which protects the retina from numerous substances in the blood (including poisons and vulnerable cells), leading to the oozing of blood ingredients into the retinal neuropile. Latterly, the basement membrane of the retinal blood vessels thickens; capillaries deteriorate and lose cells, particularly pericytes and vascular smooth muscle cells [2]. This leads to loss of blood inflow and progressive ischemia, and tiny aneurysms which appear as balloon-like structures protruding out from the capillary walls, which retain sequestered cells; and advanced dysfunction and degeneration of the neurons and glial cells of the retina. The condition generally develops about 10 - 15 years after entering the opinion of diabetes mellitus.

An experimental study suggests that pericyte death is caused by blood glucose persistently cranking protein kinase C and mitogen-activated protein kinase (MAPK), which, through a series of interceders, inhibits signaling through platelet-derived growth factor receptors - signaling that supports cellular survival, proliferation, and growth. The performing pullout of this signaling leads to the programmed cell death (apoptosis) of the cells in this experimental model.

In addition, inordinate sorbitol in diabetics is deposited on retina and it's also proposed to play a part in diabetic retinopathy. Small blood vessels - similar as those in the eye - are especially vulnerable to poor blood sugar (blood glucose) control [3]. An over accumulation of glucose damages the tiny blood vessels in the retina. During the original stage, called non-proliferative diabetic retinopathy (NPDR), utmost people don't notice any change in their vision. Early changes that are reversible and don't hang central vision are occasionally nominated background retinopathy.

A heritable study showed that diabetic retinopathy shares a analogous heritable predilection with situations of glucose, low-viscosity lipoprotein cholesterol, and systolic blood pressure, indicating that glycemic control and cardio metabolic factors may be important in the development of diabetic retinopathy [4].

As the complaint progresses, severe non-proliferative diabetic

retinopathy enters an advanced or proliferative (PDR) stage, where blood vessels gain/ grow. The lack of oxygen in the retina causes conformation of new fragile blood vessels to grow along the retina and in the clear, gel-like vitreous humor that fills the inside of the eye. Without timely treatment, these new blood vessels can bleed and beget cloudy vision, and destroy the retina [5]. Fibrovascular proliferation can also beget fractional retinal detachment. The new blood vessels can also grow into the angle of the anterior chamber of the eye and beget neovascular glaucoma.

Non-proliferative diabetic retinopathy shows up as cotton hair spots, or microvascular abnormalities or as superficial retinal hemorrhages. Indeed so, the advanced proliferative diabetic retinopathy (PDR) can remain asymptomatic for a veritably long time, and so should be covered nearly with regular checks.

Acknowledgment

The author would like to acknowledge his Department of Endocrinology, Diabetes, Metabolism, and Nutrition from the University of Mayo Clinic for their support during this work.

Conflicts of Interest

The author has no known conflicts of interest associated with this paper.

References

1. Klein R., Klein BE, Moss SE (1992) Epidemiology of proliferative diabetic retinopathy. *Diabetes care* 15(12): 1875-1891.
2. Gündüz K, Bakri SJ (2007) Management of proliferative diabetic retinopathy. *Compr Ophthalmol Update* 8(5): 245-256.
3. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, et al., (1998) Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report# 18. *Invest Ophthalmol Vis Sci* 39(2): 233-252.
4. Hietala K, Forsblom C, Summanen P, Groop PH, FinnDiane Study Group (2008) Heritability of proliferative diabetic retinopathy. *Diabetes* 57(8): 2176-2180.
5. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, et al., (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. *Am J Ophthalmol* 118(4): 445-450.

*Corresponding author: Daniel S, Department of Endocrinology, Diabetes, Metabolism, and Nutrition, The Mayo Clinic, Rochester, Minnesota, United States, E-mail: Daniel.S@mayoclinic.org

Received: 02-Mar-2022, Manuscript No. JDCE-22-58330; Editor assigned: 04-Mar-2022, PreQC No. JDCE-22-58330(PQ); Reviewed: 09-Mar-2022, QC No. JDCE-22-58330; Revised: 11-Mar-2022, Manuscript No. JDCE-22-58330(R); Published: 18-Mar-2022, DOI: 10.4172/jdce.1000151

Citation: Daniel S (2022) A Short Note on Proliferative Diabetic Retinopathy. *J Diabetes Clin Prac* 5: 151.

Copyright: © 2022 Daniel S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.